Announcements Trials
Browse Landscape

Status

Completed 5Active not recruiting 4Recruiting 2Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Hyperlipidemias 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 5Surveys and Questionnaires 4Observation 4Blood Specimen Collection 4Drug Therapy 3Chemoradiotherapy 3Surgical Procedures, Operative 2Electrocardiography 2Echocardiography 2Capecitabine 2Biopsy 2trifluridine tipiracil drug combination 1tegafur-gimeracil-oteracil 1somapacitan 1olverembatinib 1lorlatinib 1lenvatinib 1gallium 68 PSMA-11 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Zoledronic Acid 1Tumor Burden 1Telemedicine 1Tegafur 1Stents 1Spermine Synthase 1S 1 (combination) 1Robotic Surgical Procedures 1Rituximab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Observational × lorlatinib × Clear all
NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Peking University Third Hospital

Enrolling by invitation
167 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡